CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma

Neurofibromin 1 (NF1), a tumor suppressor that negatively regulates RAS through its GTPase activity, is highly mutated in various types of sporadic human cancers, including melanoma. However, the binding partners of NF1 and the pathways in which it is involved in melanoma have not been characterized in an in depth manner. Utilizing a mass spectrometry analysis of NF1 binding partners, we revealed Calpain1 (CAPN1), a calcium-dependent neutral cysteine protease, as a novel NF1 binding partner that regulates NF1 degradation in melanoma cells. ShRNA-mediated knockdown of CAPN1 or treatment with a CAPN1 inhibitor stabilizes NF1 protein levels, downregulates AKT signaling and melanoma cell growth. Combination treatment of Calpain inhibitor I with MEKi Trametinib in different melanoma cells is more effective in reducing melanoma cell growth compared to treatment with Trametinib alone, suggesting that this combination may have a therapeutic potential in melanoma. This novel mechanism for regulating NF1 in melanoma provides a molecular basis for targeting CAPN1 in order to stabilize NF1 levels and, in doing so, suppressing Ras activation; this mechanism can be exploited therapeutically in melanoma and other cancers.

[1]  D. Cooper,et al.  The NF1 somatic mutational landscape in sporadic human cancers , 2017, Human Genomics.

[2]  K. Flaherty,et al.  Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.

[3]  Benjamin J. Raphael,et al.  A weighted exact test for mutually exclusive mutations in cancer , 2016, Bioinform..

[4]  K. Dutton-Regester,et al.  Recurrent inactivating RASA2 mutations in melanoma , 2015, Nature Genetics.

[5]  N. Ratner,et al.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor , 2015, Nature Reviews Cancer.

[6]  F. Song,et al.  Advances in targeted therapy for unresectable melanoma: new drugs and combinations. , 2015, Cancer letters.

[7]  I. Donkor.  An updated patent review of calpain inhibitors (2012 – 2014) , 2015, Expert opinion on therapeutic patents.

[8]  O. Maertens,et al.  An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. , 2014, Advances in biological regulation.

[9]  B. Taylor,et al.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. , 2014, Cancer research.

[10]  D. Esposito,et al.  Dragging ras back in the ring. , 2014, Cancer cell.

[11]  M. Meyerson,et al.  Cancer Biology and Signal Transduction Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by Ddr2 Gatekeeper Mutation and Nf1 Loss , 2022 .

[12]  K. Cichowski,et al.  Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. , 2013, Cancer discovery.

[13]  Erhan Bilal,et al.  Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling , 2013, PLoS Comput. Biol..

[14]  E. Letavernier,et al.  The Calpain/Calpastatin System Has Opposing Roles in Growth and Metastatic Dissemination of Melanoma , 2013, PloS one.

[15]  R. Sullivan,et al.  Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.

[16]  J. Soulier,et al.  Neurofibromatosis‐1 gene deletions and mutations in de novo adult acute myeloid leukemia , 2013, American journal of hematology.

[17]  K. Flaherty,et al.  Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.

[18]  D. Schadendorf,et al.  A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. , 2013, Cancer discovery.

[19]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[20]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[21]  A. Burlingame,et al.  A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. , 2012, Genes & development.

[22]  K. Flaherty,et al.  From genes to drugs: targeted strategies for melanoma , 2012, Nature Reviews Cancer.

[23]  Yuanzhi Lao,et al.  Akt: A Double-Edged Sword in Cell Proliferation and Genome Stability , 2012, Journal of oncology.

[24]  C. Der,et al.  The RAF inhibitor paradox revisited. , 2012, Cancer cell.

[25]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[26]  M. Baccarini,et al.  Raf kinases in cancer–roles and therapeutic opportunities , 2011, Oncogene.

[27]  A. Ashworth,et al.  Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen , 2011, Proceedings of the National Academy of Sciences.

[28]  N. Rosen,et al.  Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.

[29]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[30]  D. Solit,et al.  Drug discovery: How melanomas bypass new therapy , 2010, Nature.

[31]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[32]  Walter Kolch,et al.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer , 2010, Nature Reviews Cancer.

[33]  Theresa Zhang,et al.  Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors , 2010, Science Translational Medicine.

[34]  Jan Koster,et al.  NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome , 2010, Cell.

[35]  R. Beroukhim,et al.  Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. , 2009, Cancer cell.

[36]  Chenwei Wang,et al.  Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma , 2009, Nature Genetics.

[37]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[38]  I. D'Angelo,et al.  Structure and Function of Neurofibromin , 2008 .

[39]  J. Pouysségur,et al.  ERK implication in cell cycle regulation. , 2007, Biochimica et biophysica acta.

[40]  Pablo Rodriguez-Viciana,et al.  A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. , 2006, Molecular cell.

[41]  N. Carragher.  Calpain inhibition: a therapeutic strategy targeting multiple disease states. , 2006, Current pharmaceutical design.

[42]  Y. Akao,et al.  Involvement of calpain in melanogenesis of mouse B16 melanoma cells , 2005, Molecular and Cellular Biochemistry.

[43]  Rajendra K. Sharma,et al.  Overexpression of m-calpain in human colorectal adenocarcinomas. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[44]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[45]  D. E. Goll,et al.  The calpain system. , 2003, Physiological reviews.

[46]  T. Jacks,et al.  Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. , 2003, Genes & development.

[47]  T. Jacks,et al.  NF1 Tumor Suppressor Gene Function Narrowing the GAP , 2001, Cell.

[48]  M. Nakao,et al.  The involvement of calpain-independent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas , 1998, Nature Medicine.

[49]  M. Kubbutat,et al.  Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability , 1997, Molecular and cellular biology.

[50]  K. Suzuki,et al.  Calpain: novel family members, activation, and physiologic function. , 1995, Biological chemistry Hoppe-Seyler.

[51]  V. Riccardi.  The Prenatal Diagnosis of NF‐1 and NF‐2 , 1992, The Journal of dermatology.

[52]  M. Wallin,et al.  Proteolysis of tubulin and microtubule-associated proteins 1 and 2 by calpain I and II. Difference in sensitivity of assembled and disassembled microtubules. , 1988, Cell calcium.

[53]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[54]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[55]  A. Wittinghofer,et al.  GEFs and GAPs: Critical Elements in the Control of Small G Proteins , 2007, Cell.

[56]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.